Savara Inc Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Savara Inc (SVRA) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $2.10 million as of 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2017-05-09
- 2017-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $2.10M.
- 2016-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $2.50M.
- 2016-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $4.80M.
- 2016-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $5.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2017-03-31 | $2.10M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $2.50M 10-K · filed 2017-03-06 |
| 2016-09-30 | $4.80M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $5.30M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $5.90M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $4.60M 10-K · filed 2016-03-14 |
| 2015-09-30 | $4.80M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $5.20M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $4.40M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $3.30M 10-K · filed 2015-03-24 |
| 2014-09-30 | $4.00M 10-Q · filed 2014-10-31 |
| 2014-06-30 | $5.30M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $3.10M 10-Q · filed 2014-05-05 |
| 2013-12-31 | $2.60M 10-K · filed 2014-03-26 |
| 2012-12-31 | $2.60M 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |